

Pharmacy BULLETIN BOARD

Retail Issue ■ Monday January 27, 2014.

Odan Labs wishes to remind you that **Adasept® Skin Cleanser** and **Tardan® Shampoo** are ideal therapeutic replacements for the discontinued products **Tersaseptic†** and **Polytar†**.

Product	DIN	Comparative	Sizes	Odan Code	UPC
Adasept® Skin Cleanser	00266507	Tersaseptic†	250 mL	020J	776097020251
			500 mL	020L	776097020503
Tardan® Shampoo	00266493	Polytar†	250 mL	170J	776097170253
			500 mL	170L	776097170505

Adasept® Antibacterial Cleanser and **Tardan®** dandruff shampoo are prescribed by dermatologists and physicians across Canada. Both products are used in hospitals and by patients nationwide.



To order, please contact your preferred wholesaler or contact Odan at 1-800-387-9342 or by e-mail at info@odanlab.com. You can also visit our website at www.odanlab.com.

Adasept® and Tardan® are registered trademarks of Odan Laboratories Ltd.
† Tersaseptic and Polytar are trademarks of Stiefel, a GSK company

■ FROM THE NEWSWIRE ■

BURNABY, BC: Animas Canada, a division of LifeScan Canada Ltd., announced the launch of the Animas® Vibe™ insulin pump and CGM system in Canada, providing a new diabetes management solution for Canadians living with Type 1 diabetes.

TORONTO: Janssen Inc. announced that Health Canada approved STELARA® (ustekinumab) for the treatment of adult patients with active psoriatic arthritis, alone or in combination with methotrexate. It is estimated that approximately 30 per cent of Canadians living with psoriasis may develop psoriatic arthritis, a chronic autoimmune disease characterized by both joint inflammation and psoriasis skin lesions. The condition is associated with reduced quality of life and increased mortality.

MISSISSAUGA: People with HER2-positive metastatic breast cancer in Alberta will now be able to access a new treatment option through the Outpatient Cancer Drug Benefit Program of Alberta Health Services (AHS). Pertuzumab (PERJETA) and trastuzumab (HERCEPTIN) have been approved for use in combination with a taxane for the treatment of patients with HER2 positive unresectable locally recurrent or metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease or who have not relapsed within six months of receiving trastuzumab in the adjuvant setting.

DORVAL, QC: Novartis Pharmaceuticals Canada Inc. (Novartis) announced that Health Canada has approved the use of long-term once-daily dual bronchodilator Ultibro™ Breezhaler® (indacaterol 110 mcg / glycopyrronium 50 mcg) as a maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.